AD
Highly rated in
22
conditions

Dr. Arati S. Desai

Perelman Center For Advanced Medicine
Philadelphia, PA
Highly rated in
22
conditions
Specialties:Palliative Medicine | Hematology Oncology
Experience:22 Years
Clinical Trials:Currently Recruiting for 2 Trials
Accepts:New PatientsMedicare
Highly rated in
22
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Arati S. Desai's experience treating your condition:
About Dr. Arati S. Desai

Arati Desai is a Palliative Medicine specialist and a Hematologist Oncology expert in Philadelphia, Pennsylvania. Desai has been practicing medicine for over 22 years and is highly rated in 22 conditions, according to our data. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Gliomatosis Cerebri, and Bone Marrow Transplant. She is licensed to treat patients in Pennsylvania. Desai is currently accepting new patients.

Her clinical research consists of co-authoring 35 peer reviewed articles and participating in 15 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Arati S. Desai it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Arati S. Desai accepts the following insurance:

  •  Ambetter
Call to see if your plan is accepted.
Locations
3400 Civic Center Blvd, Philadelphia, PA 19104
Other Locations
Philadelphia, PA 19104
Background & Education
Graduate Institution
University Of Kentucky College Of Medicine, 2001
Specialties
Palliative Medicine
Hematology Oncology
Licenses
Hospice and Palliative Medicine in PA
Hospital Affiliations
Chester County Hospital
Hospital Of The University Of Pennsylvania
Einstein Medical Center Philadelphia
Bacharach Institute For Rehabilitation
Penn Presbyterian Medical Center
Pennsylvania Hospital
Lancaster General Hospital
Grand View Hospital
Reading Hospital
Wilmington Hospital
Languages Spoken
English
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: December 08, 2022
Intervention Type: Drug, Radiation
Study Drugs: TemozolomideLomustineRegorafenibPaxalisibVAL-083
Study Phase: Phase 2/Phase 3
A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
Enrollment Status: Recruiting
Publish Date: May 27, 2022
Intervention Type: Procedure, Device, Biological
Study Phase: Phase 2
Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Enrollment Status: Active, not recruiting
Publish Date: December 09, 2022
Intervention Type: Drug, Radiation
Study Drugs: PembrolizumabBevacizumab
Study Phase: Phase 2
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Biological, Other
Study Drugs: Anti-LAG-3 Monoclonal Antibody BMS 986016Anti-PD-1Anti-CD137
Study Phase: Phase 1
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Drug
Study Drug: Regadenoson
Study Phase: Phase 1
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Radiation, Biological, Other, Drug
Study Drugs: AdV-tkValacyclovirTemozolomideNivolumab
Study Phase: Phase 1
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Drug, Procedure
Study Drugs: BGB-290 PARP InhibitorTemozolomide
Study Phase: Phase 1/Phase 2
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Other, Drug
Study Drug: Terameprocol
Study Phase: Phase 1
Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Drug
Study Drug: BGB 324
Study Phase: Early Phase 1
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Biological, Other
Study Drug: NT-I7
Study Phase: Phase 1
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
Enrollment Status: Active, not recruiting
Publish Date: December 02, 2022
Intervention Type: Biological, Drug
Study Drugs: EncorafenibBinimetinib
Study Phase: Phase 2
Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
Enrollment Status: Suspended
Publish Date: October 19, 2022
Intervention Type: Other, Drug, Radiation
Study Drug: KRT-232
Study Phase: Phase 1
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Enrollment Status: Terminated
Publish Date: October 03, 2022
Intervention Type: Drug, Other, Radiation
Study Drug: BAL101553
Study Phase: Phase 1
Phase I Study of AZD1775 (Adavosertib) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma
Enrollment Status: Active, not recruiting
Publish Date: September 21, 2022
Intervention Type: Drug, Radiation
Study Drugs: AdavosertibTemozolomide
Study Phase: Phase 1
Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 2
View 13 Less Clinical Trials -
35 Total Publications
The University of Pennsylvania glioblastoma (UPenn-GBM) cohort: advanced MRI, clinical, genomics, & radiomics.
Journal: Scientific data
Published: February 22, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
SS
Stephen J. Schuster
Dr. Stephen J. Schuster
Hematology Oncology | Hematology
Highly rated in
32
conditions
Hematology Oncology
Hematology

Penn Medicine

Perelman Center For Advanced Medicine

3400 Civic Center Blvd, 
Philadelphia, PA 

Stephen Schuster is a Hematologist Oncology specialist and a Hematologist in Philadelphia, Pennsylvania. Schuster has been practicing medicine for over 42 years and is highly rated in 32 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Pennsylvania. Schuster is currently accepting new patients.

AM
Anthony R. Mato
Dr. Anthony R. Mato
Hematology Oncology | Hematology
Highly rated in
30
conditions
Hematology Oncology
Hematology

Memorial Hematology Lymphoma Group

3400 Civic Center Blvd, 
Philadelphia, PA 

Anthony Mato is a Hematologist Oncology specialist and a Hematologist in Philadelphia, Pennsylvania. Mato has been practicing medicine for over 21 years and is highly rated in 30 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in New Jersey and Pennsylvania. Mato is currently accepting new patients.

RM
Dr. Robert G. Maki
Hematology Oncology | Pediatrics | Oncology
Highly rated in
34
conditions
Hematology Oncology
Pediatrics
Oncology

Penn Medicine

Perelman Center For Advanced Medicine

3400 Civic Center Blvd, 
Philadelphia, PA 

Robert Maki is a Hematologist Oncology specialist and a Pediatrics expert in Philadelphia, Pennsylvania. Maki has been practicing medicine for over 31 years and is highly rated in 34 conditions, according to our data. His top areas of expertise are Liposarcoma, Adult Soft Tissue Sarcoma, Leiomyosarcoma, and Angiosarcoma. He is licensed to treat patients in New York and Pennsylvania. Maki is currently accepting new patients.